Nuvation Bio taking multimechanism approach with $275M series A

Nuvation’s lead investor believes the experience of its management team and its multitarget approach to oncology will be key differentiators as the start-up maps out a plan to deploy its $275 million series A round. The company already has a clinical development and CMC team in place to develop a pipeline that spans seven mechanisms of action.

Omega Funds led the round for Nuvation Bio Inc. Also participating were Aisling Capital, Altitude Life Science Ventures, The Baupost Group, Boxer Capital of the Tavistock Group, EDBI, EcoR1 Capital, Fidelity, Pavilion Capital, Perceptive Advisors, Redmile Group, Surveyor Capital and other undisclosed institutional investors...